Ofichem Header Ofichem Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Apontis Pharma.

    Client Virtual Booth

    APONTIS PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Apontis Pharma
    Germany Flag
    Country
    Country
    Germany
    Address
    Address
    Alfred-Nobel-Str. 10, 40789 Monheim
    Telephone
    Telephone
    +49 2173484949
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://apontis-pharma.de/en/about-apontis-pharma
    Linkedin
    Linkedin
    https://www.linkedin.com/company/apontis-pharma/about/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Apontis Pharma and Midas Pharma Agree on Further Development Partnership for The Market Launch of A Single Pill with Pan-European Intellectual Property ...

    Details:

    The aim of the partnership is the contract development of a Single Pill, Biramlo, with a combination of two leading active ingredients,bisoprolol fumarate and amlodipine for the treatment of high blood pressure (hypertension).


    Lead Product(s): Bisoprolol Fumarate,Amlodipine

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Biramlo

    Highest Development Status: Phase IVProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Midas Pharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership July 19, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    APONTIS PHARMA and Midas Pharma Announce Development Partnership to Launch Single Pill with Pan-european Intellectual Property Rights

    Details:

    The objective is the contract development of a Single Pill with a combination of three leading active ingredients, including candesartan cilexetil, amlodipine besylate and atorvastatin calcium trihydrate for the treatment of high blood pressure (hypertension).


    Lead Product(s): Candesartan Cilexetil,Amlodipine Besylate,Atorvastatin

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Midas Pharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Partnership December 14, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    lgm-pharma-m-2024-07-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search